Entering text into the input field will update the search result below

Inovio Pharmaceuticals, Inc. (INO) Q3 2022 Earnings Call Transcript

Nov. 08, 2022 7:47 PM ETInovio Pharmaceuticals, Inc. (INO)
SA Transcripts profile picture
SA Transcripts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET

Company Participants

Thomas Hong – Manager-Investor Communications

Jacque Shea – President and Chief Executive Officer

Michael Sumner – Chief Medical Officer

Peter Kies – Chief Financial Officer

Conference Call Participants

Hartaj Singh – Oppenheimer & Company


Good day and welcome to the Inovio Third Quarter 2022 Results Conference Call. [Operator instructions] Please note that this event is being recorded.

I would now like to turn the conference over to Thomas Hong. Please go ahead sir.

Thomas Hong

Thank you. Good afternoon. And thank you for joining the Inovio’s third quarter 2022 financial results conference call.

Joining me on today’s call are Dr. Jacque Shea, President and CEO; Mr. Peter Kies, Chief Financial Officer; and Dr. Michael Sumner, Chief Medical Officer. We also have other members of Inovio’s leadership here with us today who will be part of our Q&A Session.

Today’s call, we will review our corporate and financial information for the quarter ended September 30, 2022, as well as provide an update on our efforts to develop our DNA medicines platform. Following prepared remarks, we will conduct a question-and-answer segment.

During the call, we will be making forward-looking statements regarding future events and the future performance of the company. These events relate to our business plan to develop Inovio’s DNA medicines platform, which include clinical and regulatory developments and timing of clinical data readouts, along with capital resources and strategic matters. All of these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially.

We refer you to the documents we file from time to time with the SEC, which under the heading risk factors identify important factors that could cause actual results to

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.